• AFFiRiS

  Participated · Equity · Jun 2016

  Affiris develops therapeutic peptide vaccines targeting chronic diseases. Its clinical pipeline includes three drug candidates for Parkinson’s disease, multiple system atrophy (MSA) and hypercholesterolemia, with additional preclinical candidates for diabetes, allergies, asthma and Huntington’s disease. The company initiated Phase 1 development of its hypercholesterolemia and atherosclerosis prevention candidates AT04A and AT06A, which target PCSK9, and expects data from that study in Q1 2017. The PCSK9-targeting approach aims to increase LDL receptors on the liver to reduce blood LDL cholesterol. Affiris has raised approximately €130m to date, roughly half of which comes from license income and government grants. The company employs 60 staff at the Campus Vienna Biocenter in Vienna, Austria. Leadership includes CEO Oliver Siegel and newly appointed CTO Günther Staffler. AFFiRiS AG is a Vienna-based developer of tailor-made peptide vaccines for Alzheimer’s disease, atherosclerosis, Parkinson’s disease, hypertension and several other conditions. The company’s current lead indication is Alzheimer’s disease. It intends to use the €25m in equity financing to advance its wide-ranging clinical development programme. Backers include Santo VC GmbH, which committed €20m, and existing investor MIG funds, which increased its stake by €5m via its MIG 11 fund. Both Santo VC and MIG hold options to extend their combined investment by a further €30m. Co-founded by CEO Walter Schmidt and CSO Frank Mattner, AFFiRiS employs 83 staff at the Campus Vienna Biocenter.

• SuppreMol

  Participated · Series C · Dec 2010

  SuppreMol is a Martinsried/Munich, Germany–based biopharmaceutical company developing innovative therapeutics for the treatment of autoimmune diseases. Its lead candidate, SM101, is a recombinant human soluble Fc gamma receptor IIb intended to treat Primary Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE). The company closed a €15.5m Series C and intends to use the proceeds for GMP production and further clinical studies of SM101. SuppreMol plans to initiate a Phase IIa study in SLE mid next year. It is also advancing preclinical development of an anti‑FcgRIIb monoclonal antibody that may have therapeutic potential in certain autoimmune diseases. Management includes CEO Dr Peter Buckel, and the company has been awarded €1.6m in research funding by the German Federal Ministry of Education and Research (BMBF).

No current team members are available.